[Dynamics of Transgene Expression in the MVA Vaccine Vector under the Control of the p11, p13.5, pLEO160, p7.5, and mH5 Promoters and Independence of the Transgene Expression Level from the Insertion Locus].

Q3 Medicine
O V Orlova, D V Glazkova, O N Sidorova, F A Urusov, G A Shipulin, E V Bogoslovskaya
{"title":"[Dynamics of Transgene Expression in the MVA Vaccine Vector under the Control of the p11, p13.5, pLEO160, p7.5, and mH5 Promoters and Independence of the Transgene Expression Level from the Insertion Locus].","authors":"O V Orlova, D V Glazkova, O N Sidorova, F A Urusov, G A Shipulin, E V Bogoslovskaya","doi":"10.31857/S0026898425020065, EDN: GGEKOK","DOIUrl":null,"url":null,"abstract":"<p><p>The modified vaccinia virus Ankara (MVA), characterized by high immunogenicity and proven safety, is considered a promising vector for vaccine development. An undeniable advantage of the MVA vector is its high capacity and the ability to incorporate several transgenes into different loci of the viral genome, enabling the creation of multivalent vaccines that encode multiple antigens simultaneously. This study examined the expression of a transgene encoding influenza virus protein epitopes after its integration into five loci of the MVA genome. The results demonstrated that the level of transgene expression is independent of the integration locus. Additionally, the dynamics of the expression of a reporter gene encoding the Enhanced Green Fluorescent Protein (EGFP) were determined under the control of the vaccinia virus promoters p11, p13.5, pLEO160, p7.5, and mH5 upon insertion of the expression cassette into the F13L gene locus of MVA. The highest expression level, though with a delayed onset of protein synthesis, was achieved with the late promoter p11. Using the p13.5 promoter resulted in earlier synthesis of EGFP in cells and higher gene expression level compared to the promoters pLEO160, p7.5, and mH5, which provided similar levels and dynamics of the reporter gene expression. These findings may be useful for developing multi-antigenic MVA-vectored vaccines.</p>","PeriodicalId":39818,"journal":{"name":"Molekulyarnaya Biologiya","volume":"59 2","pages":"244-254"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molekulyarnaya Biologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31857/S0026898425020065, EDN: GGEKOK","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The modified vaccinia virus Ankara (MVA), characterized by high immunogenicity and proven safety, is considered a promising vector for vaccine development. An undeniable advantage of the MVA vector is its high capacity and the ability to incorporate several transgenes into different loci of the viral genome, enabling the creation of multivalent vaccines that encode multiple antigens simultaneously. This study examined the expression of a transgene encoding influenza virus protein epitopes after its integration into five loci of the MVA genome. The results demonstrated that the level of transgene expression is independent of the integration locus. Additionally, the dynamics of the expression of a reporter gene encoding the Enhanced Green Fluorescent Protein (EGFP) were determined under the control of the vaccinia virus promoters p11, p13.5, pLEO160, p7.5, and mH5 upon insertion of the expression cassette into the F13L gene locus of MVA. The highest expression level, though with a delayed onset of protein synthesis, was achieved with the late promoter p11. Using the p13.5 promoter resulted in earlier synthesis of EGFP in cells and higher gene expression level compared to the promoters pLEO160, p7.5, and mH5, which provided similar levels and dynamics of the reporter gene expression. These findings may be useful for developing multi-antigenic MVA-vectored vaccines.

[p11、p13.5、pLEO160、p7.5和mH5启动子控制下MVA疫苗载体中转基因表达的动态及转基因表达水平与插入位点的独立性]。
改性安卡拉牛痘病毒(MVA)具有较高的免疫原性和安全性,被认为是一种有前景的疫苗载体。MVA载体的一个不可否认的优势是其高容量和将几种转基因整合到病毒基因组不同位点的能力,从而能够创建同时编码多种抗原的多价疫苗。本研究检测了编码流感病毒蛋白表位的转基因在整合到MVA基因组的5个位点后的表达。结果表明,转基因表达水平与整合位点无关。此外,在牛痘病毒启动子p11、p13.5、pLEO160、p7.5和mH5的控制下,将编码增强型绿色荧光蛋白(EGFP)的报告基因插入MVA的F13L基因位点后,测定了该基因的表达动态。最高的表达水平,虽然与延迟开始的蛋白质合成,实现了晚启动子p11。与启动子pLEO160、p7.5和mH5相比,使用p13.5启动子可以更早地在细胞中合成EGFP,并且基因表达水平更高,这三种启动子提供了类似的报告基因表达水平和动态。这些发现可能有助于开发多抗原mva载体疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molekulyarnaya Biologiya
Molekulyarnaya Biologiya Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
131
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信